Agile Therapeutics Inc.’s Oct. 9 press release sure sounds like bad news: The US FDA’s Office of New Drugs “has formally denied the Company’s appeal” of the most recent rejection of Agile’s Twirla contraceptive patch.
The company’s appeal had already being denied by the Office of Drug Evaluation III, which initially considered the dispute resolution...